| Identification | Back Directory | [Name]
Nintedanib Ethanesulfonate Salt | [CAS]
656247-18-6 | [Synonyms]
Nintedani
BIBF 1120 esylate
BIBF-1120 esylate
Nintedanib esylate
Nintedanib
(Ofev)
BIBF 1120 BIBF-1120
Trinidad Neeb esylate
Intedanib ethanesulfonate
Nintedanib ethanesulfonate
Brand name OFEV. Vargatef.
Trinidad Neeb ethanesulfonate
BIBF1120 ethanesulfonate salt
Nintedanib(ethanesulfonic acid)
Nintedanib ethanesulfonate salt
BIBF1120/nintedanib ethanesulfonate salt
Nintedanib esylate. Nintedanib ethanesulfonate salt
Nintedanib Ethanesulfonate (Intedanib Ethanesulfonate)
(Z)-Methyl 3-(((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)(phenyl)methylene
BIBF1120; BIBF 1120 BIBF-1120; NINTEDANIB ESYLATE. NINTEDANIB ETHANESULFONATE SALT; INTEDANIB; BRAND NAME OFEV. VARGATEF.
(Z)-methyl 3-(((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)(phenyl)methylene)-2-oxoindoline-6-carboxylate ethanesulfonate
(3Z)-2,3-Dihydro-3-[[[4-[methyl[2-(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-1H-indole-6-carboxylic acid methyl ester ethanesulfonate
1H-Indole-6-carboxylic acid,2,3-dihydro-3-[[[4-[methyl[(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]-phenylmethylene]-2-oxo-, methylester, (3Z)-, ethanesulfonate (1:1)
1H-Indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl[2-(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-, methyl ester, (3Z)-, ethanesulfonate (1:1) | [Molecular Formula]
C31H33N5O4.C2H6O3S | [MDL Number]
MFCD26142360 | [MOL File]
656247-18-6.mol | [Molecular Weight]
649.757 |
| Chemical Properties | Back Directory | [Melting point ]
>233°C (dec.) | [storage temp. ]
-20°C Freezer | [solubility ]
DMSO (Slightly), Methanol (Slightly) | [form ]
Yellow solid. | [color ]
Light Yellow to Yellow |
| Hazard Information | Back Directory | [Description]
Nintedanib esylate is a potent, oral triple angiokinase inhibitor
developed by Boehringer Ingelheim that targets proangiogenic and
pro-fibrotic pathways mediated by the vascular endothelial growth
factor receptor, fibroblast growth factor receptor and plateletderived
growth factor receptor families, as well as Src and Flt-3
kinases. It was approved for the treatment of idiopathic pulmonary
fibrosis (IPF), a condition in which the lungs become progressively
scarred over time, by the US FDA in October 2014 and by
the EMA in January 2015. The FDA granted nintedanib esylate
fast-track, priority review, orphan product, and breakthrough
designations. The drug was also approved by the EMA in November
2014 for treatment of non-small cell lung cancer in combination
with docetaxel after first-line chemotherapy. | [Uses]
Nintedanib is a potent inhibitor of multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs). | [Definition]
ChEBI: An organosulfonate salt obtained by combining nintedanib with one molar equivalent of ethanesulfonic acid. A kinase inhibitor used for the treatment of idiopathic pulmonary fibrosis and cancer. | [Synthesis]
The synthesis of indolinone 197 commenced with commercial
4-chloro-3-nitro-benzoic acid (194)?aesterification of which preceded
displacement of the chloride by dimethyl malonate (195)
in the presence of base to generate nitrobenzene 196. Hydrogenation
of 196 under acidic conditions furnished 6-methyoxycarbonyl-
substituted oxindole 197 by decarboxylative cyclization in
87% yield. Acylation of indolinone 197 with chloroacetic anhydride
in refluxing toluene and subsequent condensation with trimethyl
orthobenzoate resulted in indolone 198, which was isolated in
86% yield over the two-step sequence. While these two steps could
reportedly be combined into a one-pot protocol using acetic anhydride
as the solvent, the stepwise procedure was found to be more
amenable for large-scale synthesis due to fewer complications
with undesired side products. Subjection of 198 to methanolic
potassium hydroxide followed by condensation with aniline
fragment 199
in refluxing methanol and then exposure to aqueous ethanesulfonic
acid in methanol provided nintedanib esylate (XXIII) in 82%
over the three-step sequence.
Aniline fragment 199 was prepared in three steps
and 82% overall yield via initial acylation of N-methyl-4-nitroaniline
200 with chloro acetylchloride followed by displacement of
the a-amidochloride with N-methylpiperazine and hydrogenative
reduction of the nitro group gave the desired aniline.183,184
| [storage]
Store at -20°C | [Properties and Applications]
Nintedanib esylate (NE) is used in the treatment of idiopathic pulmonary fibrosis (IPF) and in diverse cancers, including nonsmall cell lung cancer (NSCLC). NE has a pH-dependent solubility profile with low aqueous solubility under neutral pH and increased solubility at acidic pH. The oral bioavailability of NE is 4.7% because it is a P-gp substrate and also undergoes first-pass metabolism in the liver by esterases. However, the administration of NE along with food increases the area under the curve (AUC) and maximum concentration (Cmax) when the drug is taken with food; hence, it has a positive food effect[1]. | [References]
[1] Priyanshi Patel, Mitali Patel. “Enhanced oral bioavailability of nintedanib esylate with nanostructured lipid carriers by lymphatic targeting: In vitro, cell line and in vivo evaluation.” European Journal of Pharmaceutical Sciences 159 (2021): Article 105715.
[2] Veerareddy Arava, Surendrareddy Gogireddy. “An improved process for the synthesis of nintedanib esylate.” Synthetic Communications 47 10 (2017): Pages 975-981.
[3] Esylate, Nintedanib. “Nintedanib Esylate.” Definitions 10 1 (2020).
[4] Shabari Girinath Kala, Santhivardhan Chinni. “Bioavailability enhancement of vitamin E TPGS liposomes of nintedanib esylate: formulation optimization, cytotoxicity and pharmacokinetic studies.” Drug Delivery and Translational Research 12 11 (2022): 2856–2864. |
|
|